MedTrace Logo

A Phase III Trial Assessing the Pharmacodynamic Effect and the Tolerability of Grazax Treatment

NCT00773240 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 276

Last updated 2011-08-30

No results posted yet for this study

Summary

The study assess the pharmacodynamic effect and the tolerability of Grazax treatment initiated in the grass pollen season in subjects with seasonal grass pollen induced rhinoconjunctivitis

Conditions

  • Grass Pollen Allergy

Interventions

DRUG

Grazax

1 tablet, 75,000 SQ-T, daily during the trial period

DRUG

placebo

1 placebo tablet, matching the active treatment, daily during the trial period

Sponsors & Collaborators

  • ALK-Abelló A/S

    lead INDUSTRY

Principal Investigators

  • Kim Simonsen, MD · ALK-Abelló A/S

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-04-30
Primary Completion
2008-10-31
Completion
2009-02-28

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00773240 on ClinicalTrials.gov